PubMed Health⌕ Search

PubMed · 11154578

Exploratory synthesis in the solid state. Endless wonders.

Abstract

This article gives an overview of recent developments in three areas of solid state chemistry: (1) The discovery that centered and originally-adventitious interstitial elements Z are essential for the stability of M6X12-type cluster halides of group 3 and 4 metals has led to a large amount of new chemistry through tuning structures and compositions of AnM6(Z)X12Xn phases with the variables Z, x, and n. The corresponding metal-rich group 3 tellurides exhibit novel and more extensive metal aggregation, reflecting a decreased number of anions and valence electrons. (2) Many intrinsically metallic T5M3 phases with a Mn5Si3-type structure are formed by early transition metals T with main-group elements M. Each characteristically reacts with diverse elements (up to 15-20 each) to form stuffed interstitial versions T5M3Z of the same structure. The ranges of Z and some properties are described. Related reactions of hydrogen (often as an impurity) in Mn5Si3-, beta-Yb5Sb3-, and Cr5B3-type systems are extensive. Substantially all previous reports of beta-Yb5Sb3- and Cr5B3-type phases for divalent metals with pnictogen (As-Bi) and tetrel (Si-Pb) elements, respectively, have been for the hydrides, and about two-thirds do not exist without that hydrogen (or fluorine). (3) The developing chemistry of anionic polymetal cluster compounds of the main-group elements with alkali-metal cations is outlined, particularly for the triel elements In and Tl. These clusters lie to the left of what has been called the Zintl boundary, many are new hypoelectronic polyhedra, some may be centered by the same or another neighboring element, and so far all have been isolated only as neat solid state compounds in which specificity of cation-anion interactions seems important. Extended networks are also encountered.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J D Corbett. 2000-11-13. Exploratory synthesis in the solid state. Endless wonders.. https://doi.org/10.1021/ic0007862

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗